| __timestamp | Dynavax Technologies Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 10337679 |
| Thursday, January 1, 2015 | 22180000 | 18187286 |
| Friday, January 1, 2016 | 37257000 | 24758063 |
| Sunday, January 1, 2017 | 27367000 | 23666957 |
| Monday, January 1, 2018 | 64770000 | 30099855 |
| Tuesday, January 1, 2019 | 74986000 | 64947625 |
| Wednesday, January 1, 2020 | 79256000 | 186363444 |
| Friday, January 1, 2021 | 100156000 | 272611040 |
| Saturday, January 1, 2022 | 131408000 | 358782000 |
| Sunday, January 1, 2023 | 152946000 | 409864000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. has seen a staggering increase in SG&A expenses, growing by approximately 3,860%, from $10.3 million in 2014 to $409.9 million in 2023. In contrast, Dynavax Technologies Corporation's expenses have increased by about 760%, from $17.8 million to $152.9 million in the same timeframe.
This trend highlights the aggressive expansion and operational scaling of Intra-Cellular Therapies, Inc., especially post-2020, where their expenses surged by over 120% annually. Meanwhile, Dynavax Technologies Corporation has maintained a steadier growth trajectory, reflecting a more conservative approach. These insights provide a window into the strategic priorities and market positioning of these two biotech players.
Breaking Down SG&A Expenses: Johnson & Johnson vs Intra-Cellular Therapies, Inc.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Intra-Cellular Therapies, Inc. and Dr. Reddy's Laboratories Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Catalent, Inc.
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.